natalizumab + interferon beta-1a

This is a **combination therapy** comprised of *natalizumab*, a humanized monoclonal antibody against α4-integrin, and *interferon beta-1a*, a type I interferon used as a disease-modifying therapy. The combination was studied primarily for the treatment of **relapsing multiple sclerosis** (RMS), where it was found to reduce the rate of clinical relapses and the progression of disability compared to interferon beta-1a alone[1][3][5]. - **Natalizumab** works by binding to α4-integrins on leukocytes, blocking their interaction with vascular cell adhesion molecule-1 (VCAM-1) and mucosal addressin cell adhesion molecule-1 (MAdCAM-1). This inhibits leukocyte migration across the blood-brain barrier, thereby reducing CNS inflammation and lesion formation[2][4][6][8]. - **Interferon beta-1a** modulates immune responses, reducing pro-inflammatory cytokine release and downregulating antigen presentation, thereby slowing disease progression and relapse frequency in MS[7]. Combination therapy was associated with improved efficacy but increased risk of adverse events, including rare cases of progressive multifocal leukoencephalopathy[1][3][5].

Brand names

TysabriAvonex

Other names

TYSABRI and AVONEX